

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
14 October 2021 (14.10.2021)



(10) International Publication Number  
**WO 2021/207689 A2**

(51) International Patent Classification:

A61K 35/17 (2015.01) A61K 39/395 (2006.01)  
A61K 38/00 (2006.01) A61P 35/00 (2006.01)  
A61K 38/20 (2006.01) C07K 14/435 (2006.01)

(21) International Application Number:

PCT/US2021/026702

(22) International Filing Date:

09 April 2021 (09.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/008,564 10 April 2020 (10.04.2020) US

(71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400  
Dexter Ave. N, Suite 1200, Seattle, Washington 98109  
(US).

(72) Inventor: STIRNER, Mariana, Cota; 400 Dexter Ave. N,  
Suite 1200, Seattle, 98109 (US).


(74) Agent: RICE, Rachel et al.; Morrison & Foerster LLP,  
12531 High Bluff Drive, Suite 100, San Diego, California  
92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS AND USES RELATED TO CELL THERAPY ENGINEERED WITH A CHIMERIC ANTIGEN RECEPTOR  
TARGETING B-CELL MATURATION ANTIGEN

FIG. 1



(57) Abstract: Provided are methods and uses related to adoptive cell therapy involving the administration of doses of cells, such as T cells, for treating disease and conditions, including certain plasma cell malignancies. The cells express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM).

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *without international search report and to be republished  
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*